Aardvark Therapeutics, Inc. Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Tien-Li Lee
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4370 La Jolla Village Drive San Diego CA United States of America 92122
- IPO Date
- Feb 13, 2025
- CIK
- 0001774857
- Website
- aardvarktherapeutics.com
- Similar Companies
- Business
- Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that activate innate homeostatic pathways to suppress hunger for the treatment of metabolic diseases including Prader-Willi Syndrome (PWS) hyperphagia, obesity, and obesity-related conditions; the company offers ARD-101, an oral TAS2R bitter taste receptor agonist in Phase 3 clinical development primarily for hyperphagia in PWS via localized gut hormone release and gut-brain signaling to inhibit hunger discomfort; ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor advancing into two Phase 2 trials (POWER and STRENGTH) to address GLP-1RA limitations such as weight regain post-discontinuation through weight maintenance and loss promotion; and exploratory programs like WE-868 targeting hunger-associated indications and complementary anti-appetite therapies. Founded in 2017 and headquartered in San Diego, California, Aardvark Therapeutics operates principally in the United States with a pipeline directed at endocrinology and rare genetic disorders, targeting patients with insatiable hunger in PWS and broader metabolic obesity markets. Recent developments include presentation of positive ARD-101 clinical data and ARD-201 preclinical results at ObesityWeek 2025 demonstrating metabolic benefits; reporting of third-quarter 2025 financial results with pipeline updates advancing Phase 2 trials for ARD-201; an oversubscribed $85 million Series C financing in May 2024 led by Decheng Capital to support clinical progression; a $29 million Series B funding in 2021 led by Sorrento Therapeutics; Nasdaq debut in February 2025; and inducement grants under NASDAQ rules in 2025 to bolster executive talent.
Company News
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
AARD DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action
Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action
ROSEN, A TOP RANKED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class Action - Contact SueWallSt
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately
Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately
AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline